West Pharmaceutical Services (WST) Cash from Operations (2009 - 2026)

West Pharmaceutical Services has disclosed Cash from Operations across 18 years of filings, most recently posting $124.0 million for Q2 2026.

• In Q2 2026, Cash from Operations fell 29.98% year-over-year to $124.0 million; the TTM figure through Jun 2026 stood at $662.2 million (down 2.14% YoY), while the FY2025 annual figure was $754.8 million, up 15.52% from the prior year.
• Cash from Operations came in at $124.0 million for Q2 2026 at West Pharmaceutical Services, up from $89.9 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $251.1 million in Q4 2025 to a low of $89.9 million in Q1 2026.
• Average Cash from Operations over 5 years is $173.5 million, with a median of $171.2 million recorded in 2022.
• Year-over-year, Cash from Operations jumped 70.46% in 2022 and slumped 30.53% in 2026.
• Over 5 years, Cash from Operations stood at $230.8 million in 2022, then gained by 3.6% to $239.1 million in 2023, then declined by 20.49% to $190.1 million in 2024, then soared by 32.09% to $251.1 million in 2025, then sank by 50.62% to $124.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were $124.0 million in Q2 2026, $89.9 million in Q1 2026, and $251.1 million in Q4 2025.